Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

32.63 -1.34 (-3.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdone
The companies now expect final data from the Orbit and Cosmic studies by the end of the year. 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
What's going on in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Ultragenyx Pharmaceutical Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Ultragenyx Pharmaceutical's Earnings: A Preview
 
Via Benzinga
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views
 
Via Benzinga
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028
Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027. 
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning
JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117. 
Via Benzinga
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews
 
Via Benzinga
Earnings Scheduled For February 13, 2025
 
Via Benzinga
Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views
 
Via Benzinga
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts
 
Via Benzinga
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
 
Via Benzinga
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast
 
Via Benzinga
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
Ultragenyx forecasts 2024 revenue above estimates, highlights confidence in setrusumab trial progress, and outlines plans for regulatory filings in 2025. 
Via Benzinga
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical
 
Via Benzinga
Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views
 
Via Benzinga
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells. 
Via Benzinga
Topics Lawsuit
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
 
Via Benzinga
3 Genomics Stocks That May Transform Personalized Medicine
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. 
Via InvestorPlace
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
Biogen previously decided against opting into Ionis' Angelman program. 
Via Investor's Business Daily
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
 
Via Benzinga
Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.